Under the Paperwork Reduction Act of 1995, no persons are required to respon

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10595793			
	Filing Date		2006-05-11			
First Named Inventor Jame		Jame	s Robert Bostwick			
	Art Unit		1626			
	Examiner Name	Not y	vet assigned			
Attorney Docket Number		er	101218-1P US			

Examiner Cite Patent Number		Patent Number	Kind Code ¹ Issue Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1									
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Patentee or Applicant		Relev	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1									
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d buttor		
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Line where Relevant Passages or Relevar Figures Appear	75
	1	1382613	EP		A	2004-01-21	Sumitomo Chemic	al	Whole document	
	2	9816557	wo		A	1998-04-23	General Hospital C	corp	Whole document	
	3	9947921	wo		A	1999-09-23	Pharmacopera Inc		Whole document	

U.S.PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10595793
Filing Date		2006-05-11
First Named Inventor Jame		s Robert Bostwick
Art Unit		1626
Examiner Name Not y		et assigned
Attorney Docket Number		101218-1P US

Date Considered

		NON-PATENT LITERATURE DOCUMENTS Remove					
Examiner Initials*	Cite No						
	1	DATABASE EMBL 'Online! H. Sapiens quanine binding protein 3 April 2003 XP002317000 retrieved from EBI Database accession no. BC050021 abstract					
	2	DATABASE EMBL. 'Online! Mus musculus 16 days neonate cerebellum cDNA 1 March 2003 XP002317001 retrieved from EBI Database accession no 088HKS abstract					
	3	ZiGMAN, J.M. et al., "Human Golfalpha: Complementary Deoxymbonucleic Acid Structure and Expression in Panceatic listers and Other Tissues Outside the Offsctory Neuroepithelium and Central Nervous System' Endocrimology, Baltmore, MD US, vol. 133, no. 8, December 1963, pages 2508-2514, XP000963079 ISSN: 0013-7227					
	4	BOURNE, H.R. et al., "The GTPASE Superfamily Conserved Structure and Molecular Mechanism" Nature, MacMillan Journals Ltd. London GB, vol. 349, no. 6305, 10 January 1991, pages 117-127, XP001153219 ISSN: 0028-0836					
	5	International Search Report, International Application number PCT/GB2004/004749, International Filing Date 11 November 2004					
If you wis	n to a	ld additional non-patent literature document citation information please click the Add button Add	_				

¹See Knd Codes of USPTO Patent Documents at <u>www.USPTO.COM</u> or MFEP 901 BA. ² Entire office that issued the document, by the two-letter code (WIPO Standard ST.3.) ²FeJ Japanese patent documents, the indication of the year of the neggrid of the frighted must preced the several number of the patent document. ²Knd of documents by the appropriate symbols is shadeded on the document under WIPO Standard ST.16 (\$\$\text{SSSM}\$). ²**Applicant to place a chore market produced to the common standard sta

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10595793	
	Filing Date		2006-05-11	
First Named Inventor Jame		Jame	s Robert Bostwick	
	Art Unit		1626	
Examiner Name Not y		Not y	et assigned	
	Attorney Docket Number		101218-1P US	

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.	98 to make	the appro	priate selection(s):
---------------	----------	--------	------------	-----------	----------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/t1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart to reign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(c)(c)

- 7 See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Robin S. Quartin, Reg. No. 45,028/	Date (YYYY-MM-DD)	2006-09-11			
Name/Print	Robin S. Quartin	Registration Number	45.028			

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, and Superiment of Commence, P. 0. Bot 1450, Alexandria, V.32.211-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to a patient application or patient. If you do not furnish the requested the process another examine your submission, which may visually intermediate or of redesting to a submission or the basic log process another examine; your submission, which may visually intermediate or of redesting to a submission or the submission or the submission of the submission or the submission of the submission of the submission or the submission of the submission or the submission of the submission or the submission or the submission of the submission or the submission or the submission or the

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.